Leading science in the field

Latest developments in the fields of kidney and heart health

AHA, American Heart Association; ASN, American Society of Nephrology; CKD, chronic kidney disease; CV, cardiovascular; CVOT, cardiovascular outcome trial; EASD, European Association for the Study of Diabetes; ERA-EDTA, European Renal Association-European Dialysis and Transplant Association; GLP-1RA, glucagon-like peptide-1 receptor agonist; MR, mineralocorticoid receptor; NEJM, New England Journal of Medicine; SGLT-2i, sodium-glucose co-transporter 2 inhibitor; T2D, type 2 diabetes

Click on the links below to access individual sessions at the congresses. Please note, you may have to be logged in to the congress site in some instances for direct access to the content.

ERA-EDTA:
1. Overview of the latest clinical trials
2. SGLT-2is in CKD 
3. GLP-1RAs in CKD and T2D
4. Effects of SGLT-2is on kidney and CV outcomes in CKD
5. The relationship between the MR and CKD in T2D

EASD:
6. ‘Meet the Expert’ session
7. The MR in CKD in T2D
8. VERTIS CV outcomes
9. Overview of the SGLT-2i CVOT trials
10. SGLT-2is, GLP-1RAs and the cardiorenal metabolic continuum

ASN:
11. ASN session recording
12. NEJM publication

AHA:
13. Circulation publication